It increases the risk for multiple metabolic complications including type 2 diabetes (T2D), metabolic-dysfunction associated steatotic liver disease (MASLD, previously known as non-alcoholic fatty liver disease), cardiovascular disease as well as many mechanical complications such as osteoarthritis and obstructive sleep apnoea (OSA) [3]
The study also shows that, across the obesity-related outcomes included in the study, researchers observed no reduction in medical events over the first two years of therapy
2011;34(Suppl 2):S279-S284
Considering obesity is a chronic medical condition, there should be an expectation that it will require lifelong treatmentmuch like diabetes, hypertension or any other chronic illness
This page covers what the stack is, how researchers usually schedule it, the reconstitution math for both vials, what to watch for, and how it compares to other retatrutide pairings
Quines pueden ser candidatos a Ozempic o GLP-1